1. (Original) A water dispersible tablet formulation comprising an active ingredient as beta lactam antibiotic and optionally a beta lactamase inhibitor, a disintegrating agent, said disintegrating agent being used both intragranularly and extragranularly, and pharmaceutically accepted excipients.

2. (Original) The formulation of claim 1 wherein said β-lactam antibiotic is selected from the group consisting of penicillin, cephalosporin and carbapenam.

3. (Original) The formulation of claim 1 wherein said penicillin is amoxicillin, said cephalosporins is cefuroxime axetil, cefpodoxime proxetil or cefalexin and said carbapenam is loracarbef or imipenem.

4. (Original) The formulation of claim 1 comprising the disintegrant selected from the group consisting of croscarmellose sodium, polyvinylpyrolidone and sodium starch glycolate.

5. (Currently Amended) The formulation of claim 1 ~~or 4~~ comprising about 1 % to about 2.5 % w/w of an ~~the~~ intragranular disintegrant.

6. (Currently Amended) The formulation of claim 1 ~~or 4~~ comprising about 1 % to about 5 % w/w of an ~~the~~ extragranular disintegrant.

7. (Currently Amended) The formulation of claim 1 comprising a ~~the~~ filler selected from the group consisting of lactose, microcrystalline cellulose and starch.

8. (Currently Amended) The formulation of claim 1 further ~~or 7~~ comprising 40-70 % w/w of a ~~said~~ filler.

9. (Original) The formulation of claim 1 comprising the lubricants selected from the group consisting of talc, magnesium stearate, stearic acid and colloidal silicon dioxide.

10. (Original) The formulation of claim 1 wherein said dispersible tablet has a disintegration time of less than one minute.

11. (Currently Amended) The formulation of claim 1 wherein said tablets form suspension after incorporating in aqueous media~~water~~.

12. (Original) The formulation of claim 11 wherein said suspension formed completely passes through a 750 μm sieve.

13. (Original) The formulation of claim 1 wherein said beta lactamase inhibitor is clavulanic acid or a salt thereof.

14. (Original) The formulation of claim 13 wherein the clavulanic acid salt is potassium clavulanate.

15. (Currently Amended) The formulation of claim ~~13 or~~ 14 wherein the ratio of amoxicillin to potassium clavulanate is 12:1 to 1:1.

16. (Original) The formulation of claim 15 wherein the ratio of amoxicillin to potassium clavulanate is 7:1.

17. (Currently Amended) The formulation of claim ~~1 or~~ 11 wherein the tablet when dispersed in an aqueous media, has a particle size distribution of d90 less than 600 μm.

18. (Currently Amended) The formulation of claim ~~1 or~~ 11 wherein the tablet when dispersed in an aqueous media, has a particle size distribution of d90 less than 400 μm.

19. (Currently Amended) The formulation of claim ~~1 or~~ 11 wherein the tablet when dispersed in an aqueous media, has a particle size distribution of d50 less than 300 μm.

20. (Currently Amended) A process for the preparation of a dispersible tablet comprising a beta lactam antibiotic, an optional beta lactamase inhibitor and an intragranular disintegrant, ~~said~~ the process comprising: aqueous granulating of a beta lactam antibiotic, an optional beta lactamase inhibitor and an ~~said~~ intragranular disintegrant incorporated either in the dry mix or the granulating fluid~~, are aqueous granulated, dried, mixed~~; drying the granulation; missing the dried granulation with the extragranular disintegrant, a filler, a flavour, a lubricating agent, and a sweetener; and compressing the resulting blend ~~is compressed to~~into tablets.

21. (Currently Amended) The process of claim 20 wherein the tablet ~~comprising~~comprises 30-50 % w/w amoxicillin.

22. (Currently Amended) The process of claim ~~20 or~~ 21 wherein the amoxicillin has a particle size of d_{90} less than 150 μm.

23. (Currently Amended) The process of claim ~~20 or~~ 21 wherein the amoxicillin has a particle size of d_{90} less than 75 μm.

24. (Currently Amended) The process of claim 20~~ or 24~~ wherein the tablet ~~comprising~~ comprises about 1 % to about 2.5 % w/w of intragranular disintegrant.

25. (Currently Amended) The process of claim 20~~ or 24~~ wherein the tablet ~~comprising~~ comprises about 1 % to about 5 % w/w of extragranular disintegrant.

26. (Original) The process of claim 24~~ or 25~~ wherein the disintegrant is selected from the group consisting of croscarmellose sodium, polyvinylpyrrolidone and sodium starch glycolate.

27. (New) The process of claim 25 wherein the disintegrant is selected from the group consisting of croscarmellose sodium, polyvinylpyrrolidone and sodium starch glycolate.

28. Cancelled.

29. Cancelled.

30. Cancelled.

31. (Original) The process of claim 20 wherein said granules are dried to an equilibrium relative humidity of less than at 40% at a bed temperature of not more than 60°C.

32. (Currently Amended) The process of claim ~~20~~28 wherein said granules are dried to an equilibrium relative humidity of less than 25% at a bed temperature of not more than 50°C.

33. (Original) The process of claim 20 wherein said dispersible tablet has a disintegration time of less than one minute.

34. (Currently Amended) The process of claim 20 wherein the ~~comprising~~ beta lactamase inhibitor is ~~as~~ clavulanic acid or a salt thereof, and the beta lactam antibiotic is ~~as~~ amoxicillin.

35. (Currently Amended) The process of claim ~~33~~ 31 wherein the clavulanic acid salt is potassium clavulanate.

36. (Currently Amended) The process of claim ~~33 or 34~~ 32 wherein the ratio of amoxicillin to potassium clavulanate is 12:1 to 1:1.

37. (Currently Amended) The process of claim ~~35~~ 33 wherein the ratio of amoxicillin to potassium clavulanate is 7:1.

38. (Original) The process of claim 20 wherein the tablet when dispersed in an aqueous media, has a particle size distribution of d90 less than 600 μm.

39. (Original) The process of claim 20 wherein the tablet when dispersed in an aqueous media, has a particle size distribution of d90 less than 400 μm.

40. (Original) The process of claim 20 wherein the tablet when dispersed in an aqueous media, has a particle size distribution of d50 less than 300 μm.

41. (Currently Amended) A process for the preparation of a water-dispersible tablet formulation, the process comprising:

aqueous granulation of a β-lactam antibiotic and an intragranular disintegrant, incorporated either in the dry mix or in the granulating fluid;

drying the granulated mixture;

mixing the dried granules with optional extragranular disintegrants, fillers, flavours, sweeteners, or lubricating agents; and ~~comprising~~ compressing the resulting blend to form water-dispersible tablets.

42. (Currently Amended) The process of claim ~~40~~38, wherein the β-lactam antibiotic is selected from penicillins; cephalosporins; and carbapenems.

43. (Currently Amended) The process of claim ~~40~~38, wherein the β-lactam antibiotic is amoxicillin.

44. (Currently Amended) The process of claim ~~40~~38, wherein the disintegrant is selected from croscarmellose sodium, polyvinylpyrolidone, and sodium starch glycolate.

45. (Currently Amended) The process of claim ~~43~~41, wherein the intragranular disintegrant is croscarmellose sodium.

46. (Currently Amended) The process of claim ~~43~~41, wherein the disintegrant is present intragranularly at a concentration of about 1 % to about 2.5 % w/w of the tablet formulation.

47. Cancelled.

48. Cancelled.

49. Cancelled.

50. Cancelled.

51. Cancelled.

52. Cancelled.

53. (Currently Amended) The process of claim ~~40~~38, wherein the suspension formed upon dispersion can completely pass through a 750 μm sieve.

54. A process for the preparation of a stable amoxicillin dispersible tablet formulation, ~~wherein amoxicillin and intragranular disintegrant, incorporated either in the dry mix or in the granulating fluid~~ the process comprising: granulation of amoxicillin and intragranular disintegrant; drying the granulated mixture; mixing the dried granules with optional extragranular disintegrants, fillers, flavours, sweeteners, or lubricating agents; and ~~comprising~~compressing the resulting blend to form water-dispersible tablets, wherein amoxicillin and intragranular disintegrant are incorporated either in the dry mix or in the granulating fluid.

55. (Currently Amended) The process of claim ~~53~~45, wherein amoxicillin comprises about 30 to about 50 % w/w of the formulation.

56. (Currently Amended) The process of claim ~~53~~45, wherein amoxicillin has a particle size of d_{90} less than about 150 μm.

57. (Currently Amended) The process of claim ~~53~~45, wherein amoxicillin has a particle size of d_{90} less than about 75 μm.

58. Cancelled.

59. Cancelled.

60. Cancelled.

61. Cancelled.

62. Cancelled.

63. Cancelled.

64. Cancelled.

65. Cancelled.

66. (Currently Amended) The process of claim ~~53~~45, wherein the granules are dried to an equilibrium relative humidity of less than about 40% at a bed temperature of not more than about 60°C.

67. (Currently Amended) The process of claim ~~65~~45, wherein the granules are preferably dried to an equilibrium relative humidity of less than about 25% at a bed temperature of not more than about 50°C.

68. Cancelled.

69. Cancelled.

70. Cancelled.

71. Cancelled.

72. Cancelled.

73. Cancelled.

74. (Currently Amended) The ~~A~~ process of claim 45 ~~for the preparation of a water-dispersible tablet formulation~~ wherein the tablet when dispersed in an aqueous media, has a particle size distribution of d90 less than 600 μm.

75. (Currently Amended) The process of claim ~~73~~51, wherein the d90 is less than about 400 μm.

76. (Currently Amended) The process of claim ~~73~~51, wherein the d50 is less than about 300 μm.

77. (Currently Amended) The ~~A~~ process of claim 45 ~~for the preparation of a stable, dispersible tablet formulation of amoxicillin, and intragranular disintegrant, incorporated either in the dry mix or in the granulating fluid; drying the granulated mixture; mixing the dried granules with optional extragranular disintegrants, fillers, flavours, sweeteners, or lubricating agents; and comprising the resulting blend to form water dispersible tablets,~~ wherein the tablet is bioequivalent to the amoxicillin suspension formulation available commercially under the trade name Amoxil™ as required by the USFDA.